Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Steatohepatitis Clear all
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

NCT03610945
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Fluconazole, Quinidine, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT03213145
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
intraconazole, Rifampin, EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Not applicable Interventional

Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH

NCT05357248
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
Interventions
BT-NCBT-00X
Device
Lead sponsor
Better Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Chandler, Arizona • Peoria, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 25, 2026, 10:38 AM EDT
Recruiting No phase listed Observational

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

NCT04634643
View directory record Official record
Conditions
NAFLD
Interventions
Usual diet and physical activity
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
260 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

NCT03421431
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 Dose 1, EDP-305 Dose 2, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
70
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 25, 2026, 10:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

NCT05692024
View directory record Official record
Conditions
Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis, Fibrosis, Liver, Ultrasound Elastography, Proton Magnetic Resonance Spectroscopy
Interventions
Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule., Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men

NCT04186260
View directory record Official record
Conditions
NAFLD
Interventions
NAFLD-specific weight loss intervention, Wait-list control
Behavioral · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

NCT00443079
View directory record Official record
Conditions
Fatty Liver
Interventions
IdB 1016 (Siliphos), Matched placebo
Drug
Lead sponsor
Heather Patton
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome

NCT01787591
View directory record Official record
Conditions
Non-alcoholic Fatty Liver, Metabolic Syndrome
Interventions
Fat-Free Milk, Low-Fat Milk, Full-Fat Milk, Soy Milk
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 3 Interventional

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes

NCT02132442
View directory record Official record
Conditions
Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
Interventions
Ergocalciferol, placebo
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 25, 2026, 10:38 AM EDT
Withdrawn Not applicable Interventional

Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver

NCT01849081
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
CPAP, LIfestyle
Device · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 25, 2026, 10:38 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196, Placebo, Liver Biopsy
Drug · Procedure
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
90
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 25, 2026, 10:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons

NCT00889577
View directory record Official record
Conditions
HIV Infections, Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

NCT00998335
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 25, 2026, 10:38 AM EDT
Recruiting Phase 2 Interventional

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis
Interventions
Placebo, ECC4703, ECC0509
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
64
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 10:38 AM EDT
Terminated Phase 2 Interventional Results available

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02605616
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Interventions
AZ compound, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 1 Interventional

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05395481
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions
LY3849891, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Orange, California • Rialto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
120
States / cities
Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Not applicable Interventional

Feasibility of VIIT in Adults With NASH

NCT03861819
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Diseases
Interventions
Vigorous-intensity interval training (VIIT)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 25, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

NCT03681457
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
LJN452
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 25, 2026, 10:38 AM EDT
Not listed Not applicable Interventional

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

NCT01511523
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
RGMA001, Sugar Pill
Dietary Supplement
Lead sponsor
Biovil Research Group, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 25, 2026, 10:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Early Tracking of Childhood Health Determinants (ETCHED) Study

NCT03481829
View directory record Official record
Conditions
Diabetes Mellitus, Obesity, Fatty Liver
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2041
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 10:38 AM EDT